Company intelligence / Profile preview
Novadip Biosciences
Mont-Saint‑Guibert, Belgiumnovadip.com ↗
- Ownership
- Private
- Employees
- ~45
- Development stage
- Other
01
Overview
Novadip has demonstrated strong clinical proof-of-concept for its autologous therapy NVD003 in congenital pseudarthrosis of the tibia and adult nonunion fractures. Its allogeneic product NVDX3 has shown high rates of durable bone union with no related adverse events at one year post-treatment. Both products are advancing toward pivotal trials.
- Therapeutic areas
- OtherRare DiseasesRheumatology
- Modalities
- Autologous cell-based therapies (using adipose-derived stem cells)Allogeneic cell-based therapies (off-the-shelf bone grafts)Exosome/miRNA-based therapeutics (early stage)Tissue engineering/scaffold-free constructs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Novadip Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novadip Biosciences.